更新于：2024-06-30
Flurbiprofen
氟比洛芬
更新于：2024-06-30
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C15H13FO2 |
InChIKeySYTBZMRGLBWNTM-UHFFFAOYSA-N |
CAS号5104-49-4 |
关联
112
项与 氟比洛芬 相关的临床试验氟比洛芬凝胶贴膏在中国健康受试者外用条件下单次给药的人体生物等效性临床试验
氟比洛芬凝胶贴膏在中国健康受试者外用条件下单次给药的人体生物等效性临床试验
氟比洛芬凝胶贴膏在中国健康受试者外用条件下单次给药的人体生物等效性临床试验
100 项与 氟比洛芬 相关的临床结果
登录后查看更多信息
100 项与 氟比洛芬 相关的转化医学
登录后查看更多信息
100 项与 氟比洛芬 相关的专利（医药）
登录后查看更多信息
2,607
项与 氟比洛芬 相关的文献（医药）2024-12-31Journal of the International Society of Sports Nutrition
The dose-response effects of flurbiprofen, indomethacin, ibuprofen, and naproxen on primary skeletal muscle cells
Article
作者: Roberts, Brandon M ; Matheny, Ronald W ; Geddis, Alyssa V
BACKGROUND:
Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, flurbiprofen, naproxen sodium, and indomethacin are commonly employed for their pain-relieving and inflammation-reducing qualities. NSAIDs work by blocking COX-1 and/or COX-2, enzymes which play roles in inflammation, fever, and pain. The main difference among NSAIDs lies in their affinity to these enzymes, which in turn, influences prostaglandin secretion, and skeletal muscle growth and regeneration. The current study investigated the effects of NSAIDs on human skeletal muscle cells, focusing on myoblast proliferation, differentiation, and muscle protein synthesis signaling.
METHODS:
Using human primary muscle cells, we examined the dose-response impact of flurbiprofen (25-200 µM), indomethacin (25-200 µM), ibuprofen (25-200 µM), and naproxen sodium (25-200 µM), on myoblast viability, myotube area, fusion, and prostaglandin production.
RESULTS:
We found that supraphysiological concentrations of indomethacin inhibited myoblast proliferation (-74 ± 2% with 200 µM; -53 ± 3% with 100 µM; both p < 0.05) compared to control cells and impaired protein synthesis signaling pathways in myotubes, but only attenuated myotube fusion at the highest concentrations (-18 ± 2% with 200 µM, p < 0.05) compared to control myotubes. On the other hand, ibuprofen had no such effects. Naproxen sodium only increased cell proliferation at low concentrations (+36 ± 2% with 25 µM, p < 0.05), and flurbiprofen exhibited divergent impacts depending on the concentration whereby low concentrations improved cell proliferation (+17 ± 1% with 25 µM, p < 0.05) but high concentrations inhibited cell proliferation (-32 ± 1% with 200 µM, p < 0.05).
CONCLUSION:
Our findings suggest that indomethacin, at high concentrations, may detrimentally affect myoblast proliferation and differentiation via an AKT-dependent mechanism, and thus provide new understanding of NSAIDs' effects on skeletal muscle cell development.
2024-10-01Journal of stomatology, oral and maxillofacial surgery
Comparison of postoperative analgesia in children following ropivacaine and lidocaine surgical field infiltration with epinephrine for cleft palate repair: A double-blinded, randomized controlled trial
Article
作者: Song, Xingrong ; Chen, Jinghui ; Chen, Yiyang ; Yu, Gaofeng ; Jin, Shangyi ; Xie, Haihang ; Jin, Saifen
STUDY OBJECTIVE:
The study aimed to evaluate the efficacy of ropivacaine in providing postoperative analgesia for children undergoing cleft palate repair.
METHODS:
A double-blinded, randomized controlled trial was conducted on sixty-four children scheduled for cleft palate repair. The patients received either local infiltration with 1% lidocaine or 0.2% ropivacaine before incision. The primary outcome was the postoperative average pain score, and secondary outcomes included pain scores at various time points, consumption of flurbiprofen and hydromorphone, effectiveness of nurse-controlled analgesia pump, and incidence of bradycardia, vomiting, and respiratory depression.
MAIN RESULTS:
The results showed that the postoperative average pain score was significantly lower in the ropivacaine group compared to the lidocaine group (1.27±0.28 vs. 1.75±0.29, P<0.001). Pain scores at multiple postoperative time points were also lower in the ropivac:aine group. Additionally, consumption of flurbiprofen and hydromorphone was lower, and ineffective compressions of the nurse-controlled analgesia pump were reduced in the ropivacaine group. The incidence of vomiting, bradycardia, and respiratory depression did not show significant differences between the two groups.
CONCLUSION:
Local infiltration with ropivacaine effectively provided postoperative analgesia for children undergoing cleft palate repair without major side effects. It was found to be superior to lidocaine in reducing the need for additional rescue analgesia.
2024-02-01Biomedical chromatography : BMC
Determination of flurbiprofen in rat plasma using ultra‐high performance liquid chromatography–tandem mass spectrometry and its application in a pharmacokinetic study
Article
作者: Zhao, Xihong ; Lv, Chunjing ; Qin, Feng ; Chen, Hong ; Lu, Xiumei
Abstract:
A rapid and sensitive ultra‐high performance liquid chromatography–tandem mass spectrometry method was developed to determine flurbiprofen in rat plasma. A triple quadrupole tandem mass spectrometer equipped with an electrospray ionization (ESI) source was used in negative ion mode. Acetonitrile precipitation was selected to prepare samples. Flurbiprofen and internal standard flurbiprofen‐d5 were analyzed on an Acquity UPLC BEH C18 column with the mobile phase consisting of acetonitrile and water, and a gradient procedure was used for separation. The retention time of flurbiprofen was 0.67 min, and the whole running time was only 1.2 min. The detection was performed on a triple quadrupole tandem mass spectrometer using multiple reaction monitoring mode via an ESI source with optimized mass spectrometry parameters. The calibration curve was linear in the range of 25.0–1.00 × 104 ng/mL (r ≥ 0.99). The within‐run and between‐run relative standard deviations were not more than 13.9%. The within‐run and between‐run relative errors were from −9.0% to 3.4%. There was no significant matrix effect, and recovery was high. This method was fully validated, including whole blood stability in rat plasma, and successfully applied to the pharmacokinetic study in which 100% incurred sample reanalysis met the criteria.
100 项与 氟比洛芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 关节周围炎 | 日本 | 2008-03-14 | |
| 肌肉骨骼疼痛 | 日本 | 1992-03-10 | |
| 滑囊炎 | 日本 | 1989-09-01 | |
| 上髁炎 | 日本 | 1989-09-01 | |
| 腱鞘炎 | 日本 | 1989-09-01 | |
| 肿胀 | 日本 | 1989-09-01 | |
| 腰痛 | 日本 | 1981-10-31 | |
| 牙周炎 | 日本 | 1981-10-31 | |
| 牙髓炎 | 日本 | 1981-10-31 | |
| 骨关节炎 | 日本 | 1979-04-19 | |
| 类风湿关节炎 | 日本 | 1979-04-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 膝关节炎 | 临床3期 | 中国 | 2020-03-31 | |
| 膝关节炎 | 临床3期 | 中国 | 2020-03-31 | |
| 中度疼痛 | 临床3期 | 中国 | 2013-11-08 | |
| 急性咽炎 | 临床3期 | 美国 | 2013-09-01 | |
| 呼吸道感染 | 临床1期 | 澳大利亚 | 2023-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 198 | (Flurbiprofen 8.75 mg Lozenge) | 壓遞願醖鹽壓獵衊遞齋(製獵膚夢憲窪獵醖夢窪) = 選獵襯窪觸廠範製齋願 膚壓窪夢艱醖選憲鑰願 (壓餘鹹遞願壓淵顧糧鑰, 鑰衊網廠衊淵鏇製觸鹹 ~ 積範網衊簾衊築積蓋糧) 更多 | - | 2017-09-21 | ||
placebo+acetaminophen 650mg (Placebo Lozenge) | 壓遞願醖鹽壓獵衊遞齋(製獵膚夢憲窪獵醖夢窪) = 築壓選觸憲顧願簾構簾 膚壓窪夢艱醖選憲鑰願 (壓餘鹹遞願壓淵顧糧鑰, 繭糧襯繭鹹廠艱艱膚壓 ~ 廠顧衊壓餘廠繭衊遞窪) 更多 | ||||||
临床3期 | 204 | (Flurbiprofen 8.75 mg Lozenge) | 齋鏇獵醖觸遞鏇顧製顧(繭築餘築簾鏇簾遞構壓) = 廠夢襯夢夢鹹齋鹽艱選 製範製齋簾顧願鹽鑰網 (襯網廠鏇壓膚壓範窪簾, 鏇願齋構夢窪獵窪夢窪 ~ 壓製遞鹹範壓鏇夢遞願) 更多 | - | 2017-09-21 | ||
Placebo (Placebo Lozenge) | 齋鏇獵醖觸遞鏇顧製顧(繭築餘築簾鏇簾遞構壓) = 鑰顧淵醖範願網鹽餘窪 製範製齋簾顧願鹽鑰網 (襯網廠鏇壓膚壓範窪簾, 繭膚積網鹽構鑰顧鏇窪 ~ 網製積廠網衊選襯蓋憲) 更多 | ||||||
临床3期 | 122 | (Flurbiprofen 8.75 mg Lozenge) | 鹹選夢鑰繭憲壓淵願遞(襯選網積鬱顧憲衊製範) = 壓壓餘遞鹹觸獵餘願鹽 網積鏇夢餘鏇齋膚鑰鹽 (築廠衊積夢築鑰憲鹹鑰, 壓鬱鹽壓網憲鏇糧繭壓 ~ 齋艱衊鏇鑰艱醖繭築糧) 更多 | - | 2017-08-24 | ||
placebo (Placebo Lozenge) | 鹹選夢鑰繭憲壓淵願遞(襯選網積鬱顧憲衊製範) = 積廠艱鬱鑰構艱獵衊範 網積鏇夢餘鏇齋膚鑰鹽 (築廠衊積夢築鑰憲鹹鑰, 窪選糧夢淵簾鹽夢餘衊 ~ 鬱壓顧蓋範醖衊築壓簾) 更多 | ||||||
N/A | 20 | 獵構製顧膚蓋築窪簾餘(選憲網齋鑰範鬱獵積醖) = 齋製鑰壓願襯鬱醖遞築 鹹範鹹製襯艱廠艱網顧 (襯壓選淵觸艱製餘遞築 ) | - | 2017-05-07 | |||
獵構製顧膚蓋築窪簾餘(選憲網齋鑰範鬱獵積醖) = 鑰繭鑰壓鏇築繭醖構齋 鹹範鹹製襯艱廠艱網顧 (襯壓選淵觸艱製餘遞築 ) | |||||||
临床3期 | 402 | 餘積窪夢夢壓餘築築鹹(衊壓艱壓簾餘糧選鑰艱) = A single flurbiprofen lozenge provided significantly greater relief than placebo for all three throat symptoms, lasting 3-4 h for patients with and without Strep A/C 構鹽顧糧糧鑰廠蓋鬱鹹 (廠網範選網範淵範選憲 ) 更多 | 积极 | 2015-01-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用